StreetAlpha.app
Home › Stocks › CRIS

Curis Inc (CRIS)

$0.54
▲ +24.32%
LAST CLOSE · NOV 17

Curis is a Lexington, Massachusetts biotechnology company developing emavusertib, an oral drug candidate for blood cancers. It last closed at $0.54 on Nov 17, up 24.32% on the day.

AI Auto Pilots
Is CRIS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$21.5M
Valuation
Market cap
$5.2M
9.5M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$5.0M
At Sep 30
Shareholder equity
$2.6M
Shares outstanding
9.5M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $10.6M$10.6MFY2021FY2022: $10.2M$10.2MFY2022FY2023: $10.0M$10.0MFY2023FY2024: $10.9M$10.9MFY2024FY2025: $9.4M$9.4MFY2025

From CRIS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated CRIS in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 1007.4% upside

Based on 1 analyst who set a price target on CRIS in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $0.54.

Low $6.00Avg $6.00High $6.00
Blue marker: last close $0.54
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 13Buy$43 → $6
HC Wainwright & Co.Reiterated
Aug 17Buy$43
HC Wainwright & Co.Maintained
Jul 24Buy$43
DateFirmActionRatingPrice target
Nov 13HC Wainwright & Co.Target loweredBuy$43 → $6
Aug 17HC Wainwright & Co.ReiteratedBuy$43
Jul 24HC Wainwright & Co.MaintainedBuy$43
Loading…

Technical Analysis

CRIS · as of the Nov 17 close · updated after every close
Downtrend

The stock is 8% below its 20 day and 35% below its 50 day average. It is 1371% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 44). The nearest support is the Pivot at $0.51, and the nearest resistance the Pivot R1 at $0.58.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 32.5%/day
Key levels
$28.4052 week high+5159.3%
$7.97200 day average+1375.9%
$2.28100 day average+322.2%
$0.82Swing high (Oct 8)+51.9%
$0.7350 day average+35.2%
$0.5920 day average+9.3%
$0.58Pivot R1+7.4%
$0.54Last close
$0.51Pivot−5.6%
$0.48Pivot S1−11.1%
$0.36Swing low (Oct 26)−33.3%
$0.3352 week low−38.9%
Indicators
RSI (14)44.35Middle of its rangeNeutral
MACD-0.06Below its signal lineBearish
Stochastic6.6Near the bottom of its rangeOversold
ADX (14)35.5Trending up
Williams %R-89.4Oversold below −80, overbought above −20Oversold
CCI (20)-35.5Oversold below −100, overbought above 100Neutral
Rate of change−22.5%Change over 10 sessionsBearish
ATR (14)$0.18Typical daily range, 32.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRIS

What happened before

See how CRIS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CRIS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CRIS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CRIS in the last 90 days.

Loading…

See today’s whale options flow across the market →

CRIS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼27 buying vs 39 selling
  • ▼Held by funds -128.8 pts
  • ▼Funds holding -11
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2839−28.2%
In funds' top 10110.0%
Held by funds12.2%141.0%−128.8 pts
New / increased27 / 07 / 5+125.0%
Reduced / sold out1 / 3810 / 12+77.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CRIS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRIS is in one of them and how their past CRIS trades turned out.

CRIS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CRIS in an article yet. Here's the latest on the wider market.

About Curis

Curis is a biotechnology company based in Lexington, Massachusetts, that is developing emavusertib, an oral small molecule drug candidate for blood cancers. The drug is designed to block two cell signaling proteins, IRAK4 and FLT3, which help certain leukemias and lymphomas grow and survive. Curis is testing emavusertib in clinical studies for patients with relapsed or refractory primary central nervous system lymphoma and for patients with chronic lymphocytic leukemia, both in combination with other cancer drugs. The company does not yet have an approved product for sale, so its patients are those enrolled in its clinical trials.

Headquarters
Lexington, MA